Sign In
Section Navigation
Common TitleAPV30005
Official Title An Open-Label Phase III Study to Assess the Long Term Safety Profile of Fosamprenavir (GW433908) Containing Regimens in HIV-1 Infected Subjects
Phase Phase III
ClinicalTrials.gov NCT00296504
Treatments
Fosamprenavir
Fosamprenavir Lexiva

Fosamprenavir

Tradename:LexivaOther Names:FPVClass:Protease Inhibitors (PI)
Categories Treatment-NaivePharmacologyAdverse Effects
Funding
IndustryViiV Healthcare
References
  • Gathe JC Jr, Wood R, Sanne I, et al. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006;28:745-54.
    [PubMed Abstract]
  • Wood R, Gathe JC, Givens N, Sedani S, Cheng K, Sievers J. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients. HIV Clin Trials. 2013;14:183-91.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.